Novus Acquisition & Development Corp. (NDEV) Stock Price & Analysis
Novus Acquisition & Development Corp. (NDEV) — price $0.0125 (+13.64%), as of the Nov 19, 2026 trading session; market cap $1.61M.
Educational signal · not a buy or sell recommendation · How to read this
Novus Acquisition & Development Corp. · NDEV
Novus Acquisition & Development Corp. operates as an insurance company, focusing on health policies within the cannabis space. The company offers a range of benefit plans and THC health plans in California.
Price as of Nov 19, 2026
Key Statistics
Not scored: this is a debt/preferred or other non-common instrument, or its reported market value does not match its share basis.
Price & valuation
| Measure | Value | As of |
|---|---|---|
| Latest provided price | $0.0125 | |
| Change on the day | +13.64% | |
| 52-week range | $0.0028 – $0.026 | |
| Market capitalisation | $1.61M | — |
| Price / earnings (trailing) | 15.71 | |
| Shares traded on the day | 26.9K |
Price & events
What is Novus Acquisition & Development (NDEV), and what does it report?
Short answer
A current FMP business description is unavailable; the listing and provider classification below are the available identity facts. Novus Acquisition & Development Corp. (NDEV) is the company analyzed here. It employs 1 people and is led by Gary Frank Labrozzi. In Q2 FY2026 it reported revenue of $107,785 and net income of $50,838. The market values it at $1.61M.
What do the latest results show for Novus Acquisition & Development (NDEV)?
Short answer · as of
The most recent reported quarter, Q2 FY2026, carried revenue of $107,785.
Quarterly income statement — 4 quarters
| Period | Revenue | Net income | EPS |
|---|---|---|---|
| Q2 FY2026 | $107,785 | $50,838 | $0.00 (diluted) |
| Q1 FY2026 | $106,613 | $47,755 | $0.0004 (diluted) |
| Q4 FY2025 | $104,844 | $42,664 | $0.0003 (diluted) |
| Q3 FY2025 | $102,347 | $55,233 | $0.0004 (diluted) |
What are the financial strengths and risks for Novus Acquisition & Development (NDEV)?
Short answer · as of
The distress and quality screens read Altman Z -0.55 · Piotroski F 4. Trailing ratios: ROE 10.3% · ROA 10.0% · current ratio 1.43 · earnings yield 10.0%.
The records behind this page
Who holds the shares?
Institutional ownership reported through 13F filings.
Tracked investors
Which of the 16 named investors we follow held NDEV in their latest 13F filing, and what they did against the filing before it.
None of the 16 tracked investors reported NDEV in their latest 13F filing.
How to read these figures
These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.
Novus Acquisition & Development Stock: Key Questions Answered
These answers are editorial: 1 of these 1 answer is drawn from the NDEV research dossier (written Mar 17, 2026 by gemini-2.0-flash). Figures in this section are not part of the source register.
What are the main risks for NDEV?
The main risks for Novus Acquisition & Development Corp. include regulatory changes in the cannabis industry, which could impact the legality and marketability of its insurance products.
Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated Mar 17, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.
Sources: the source register lists the 14 figures on this page — 8 from Financial Modeling Prep (FMP) and 6 with no recorded source. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.
Publication details and research sources
- Published
- Research standards
- Methodology · Editorial policy · Corrections
- Report a number
- sedat@stockexpertai.com